New Compact Cyclotron Improves Cancer Imaging Access
The new MINItrace Magni cyclotron enables on-site production of vital isotopes for patients requiring PET scans.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you trust that new medical imaging tech will make diagnostic testing more accessible in your area?
GE HealthCare has received a CE Mark for its MINItrace Magni cyclotron, a compact system designed for the production of PET isotopes. This development aims to improve access to radiotracers, which must be created near patients due to their short half-lives.
Why it matters
Many medical imaging isotopes used in PET scans decay rapidly, making local production vital for timely clinical use. This technology helps hospitals and research centers streamline the creation of these essential diagnostic tools on-site.
The MINItrace Magni, which recently received a CE Mark, offers a compact footprint of 7.2 square meters for the production of short-lived isotopes like fluorine-18. While its regulatory clearance is finalized, the clinical impact of its streamlined workflow awaits broader real-world deployment.
The players
GE HealthCare
A global medical technology company specializing in imaging, ultrasound, and radiopharmaceutical solutions.
The details
The system utilizes a three-click workflow that automates target preparation and radiation beam tuning to simplify isotope production. By facilitating the local generation of fluorine-18, carbon-11, oxygen-15, and nitrogen-13, the device addresses the logistical challenges posed by the short half-lives of these tracers. Additionally, the expanded PETtrace platform now supports the production of copper-64, an isotope currently under investigation for potential roles in highlighting and targeting prostate and breast cancer cells.
Timeline
October 15, 2026: GE HealthCare announced the CE Mark approval for the MINItrace Magni.
2026: Zirconium-89 production capabilities debuted earlier this year.
Health Landscape
The advancement of compact, on-site cyclotrons reflects a shift toward decentralizing radiopharmaceutical production. This evolution builds upon the established PETtrace cyclotron platform to meet the growing need for precision imaging and therapeutic isotopes in oncology.
Increased local availability of PET isotopes can mean faster access to specialized diagnostic scans that help oncologists track tumor activity. Patients undergoing cancer staging or follow-up imaging should consult their physicians about how advancements in local tracer production might impact their diagnostic scheduling.
The takeaway
The move toward compact isotope production aims to shorten the path between manufacturing and patient care. Individuals monitoring cancer developments may want to follow research regarding copper-64, which is currently being studied for potential diagnostic and therapeutic use.
Further reading
For more on the role of medical imaging in oncological diagnostics, see our Cancer section.
Live Poll
Do you trust that new medical imaging tech will make diagnostic testing more accessible in your area?
